Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

70P - A DNA methylation markers panel for prediction of luminal B breast cancer neoadjuvant chemotherapy response by quantitative PCR

Date

16 Sep 2021

Session

ePoster Display

Topics

Basic Science

Tumour Site

Breast Cancer

Presenters

Aleksandra Nikolaeva

Citation

Annals of Oncology (2021) 32 (suppl_5): S382-S406. 10.1016/annonc/annonc686

Authors

A. Nikolaeva1, V. Sigin1, A.I. Kalinkin1, N.V. Litviakov2, E. Slonimskaya2, M. Tsyganov2, A. Kharitonova3, I. Vinogradov4, M. Vinogradov5, V.V. Strelnikov1, A.S. Tanas1, I. Vinogradov4

Author affiliations

  • 1 Epigenetics, Research Centre for Medical Genetics, 115478 - Moscow/RU
  • 2 Cancer Research Institute, Tomsk National Research Medical Center, 634005 - Tomsk/RU
  • 3 Branch Of The National Medical Research Radiological Center Of The Ministry Of Health Of The Russian Federation (a. Tsyb Mrrc), A. Tsyb Medical Radiological Research Center, 249036 - Obninsk/RU
  • 4 Pathology And Anatomy Department With Pathology Laboratory, Ryazan Regional Clinical Oncology Dispensary, 390011 - Ryazan/RU
  • 5 Oncology, Ryazan State Medical University, 390026 - Ryazan/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 70P

Background

Emergence of genome-wide DNA methylation screening techniques allowing identification of differentially methylated regions that discriminate groups of clinically different samples has stimulated development of epigenetic diagnostic tests, especially for applications in cancer diagnostics. Translation of markers identified on genome-wide datasets into clinically applicable tests requires specific test systems design and validation on independent cohorts. Objective of this study was to select DNA methylation markers for prediction of luminal B breast cancer (BC) neoadjuvant chemotherapy (NACT) response from the genome-wide DNA methylation sequencing results; to design quantitative PCR assays for their detection, and to estimate their diagnostic values in order to provide a panel for accurate prediction of response to NACT.

Methods

Genome-wide methylation analysis of 43 luminal B subtype BC biopsy specimens taken before NACT was performed by bisulfite sequencing (XmaI-RRBS). Informative DNA methylation markers were selected from XmaI-RRBS data using the Wilcoxon–Mann–Whitney test. For these markers, Methylation Sensitive Restriction Enzyme qPCR (MSRE-qPCR) assays were designed and an independent cohort of 35 luminal B samples was assessed. Most informative markers were combined in panels and assessed by multiplex MSRE-qPCR. The area under the ROC curve (AUC) with cross-validation was calculated for each panel.

Results

Best NACT response DNA methylation classifier for luminal B breast cancer includes CpG islands of TTC34, LTBR and CLEC14A genes. For LTBR, lower methylation levels predict higher NACT efficacy, with AUC of 69%, while for TTC34 and CLEC14A higher NACT efficacy was associated with higher methylation levels, with AUCs of 56% and 57% respectively. Combination of the three markers in a panel enhances diagnostic values to AUC of 76%, sensitivity of 70% and specificity of 79%.

Conclusions

A three-gene DNA methylation markers panel including TTC34, LTBR and CLEC14A genes accurately predicts luminal B breast cancer response to NACT and is adapted for potential clinical application, being implemented as a multiplex MSRE-qPCR assay for use with real-time PCR instruments.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Research Centre for Medical Genetics, Moscow, Russian Federation.

Funding

Russian Science Foundation (project No.18-15-00430).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.